Argos Therapeutics, a Durham, North Carolina-based biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases, has raised $25m in Series D financing.
The round was led by Forbion Capital, with participation from existing investors TVM Capital, Lumira Capital, Intersouth Partners, Caisse de depot et placement du Quebec, Morningside Group, and Aurora Funds.
Led by Charles Nicolette, Ph.D., chief scientific officer and vice president of research and development, Argos Therapeutics focuses on the development and commercialization of immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis™ technology platform. Using biological components from each patient, Arcelis-based immunotherapies employ the patient’s dendritic cells to activate an immune response specific to the patient’s disease. Argos’ most advanced product candidates include AGS-003 for the treatment of metastatic renal cell carcinoma, or mRCC, and AGS-004 for the treatment of HIV.
The company intends to use the funding to support the commencement of its Phase 3 ADAPT study in patients with newly diagnosed, metastatic renal cell carcinoma (mRCC) in mid-2012.